Review: Treatment of primary biliary cirrhosis
- 1 July 1996
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 11 (7) , 605-609
- https://doi.org/10.1111/j.1440-1746.1996.tb00300.x
Abstract
Primary biliary cirrhosis (PBC) is a slowly progressive chronic cholestatic disease of the liver thought to be caused by immune destruction of the interlobular bile ducts. One‐third of patients are asymptomatic and one‐third of these develop symptoms within 5 years. Therapeutic regimens should be directed at the control of symptoms, prevention of complications and specific therapy aimed at controlling progression of the disease. Symptoms may be secondary to cholestasis or due to other associated diseases. The cause of pruritus secondary to cholestasis remains unknown; the anion exchange resin cholestyramine generally brings relief. In patients resistant or intolerant to this therapy, rifampin may be helpful, as well as ultraviolet light without sunblock. Liver transplantation may rarely be the only option for uncontrollable pruritus. Clinical manifestations of keratoconjunctivitis sicca and xerostomia need constant attention to prevent corneal ulcers and dental caries. Preventative therapy includes regular screening for thyroid dysfunction and replacement therapy when necessary and the administration of the fat soluble vitamins A, D and K once hyperbilirubinaemia is present. Osteoporosis is a complication of all cholestatic liver disease. There is no satisfactory preventative therapy. It may be appropriate to give hormone replacement therapy to all post‐menopausal women with PBC to reduce osteoporosis. Liver transplantation is the best option for those with fractures. Oesophageal varices may develop early in the course of PBC, non‐selective beta‐blocker therapy should be used as prophylaxis against variceal haemorrhage. The only specific therapy shown to cause both a biochemical and survival benefit in patients with PBC is ursodeoxycholic acid (UDCA). Treatment with UDCA delays progression, but does not result in a cure of this disease. Currently, liver transplantation is the only definitive treatment available for end‐stage disease.Keywords
This publication has 31 references indexed in Scilit:
- Ursodeoxycholic acid therapy in primary biliary cirrhosisHepatology, 1995
- The Canadian multi-center double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Heathcote EJ, Cauch-Duder K, Walker V, Bailey RJ, Blendis LM, Ghent CM, Michieletti P, et al. 1994;19:1149?1156Hepatology, 1995
- Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 yearsJournal of Hepatology, 1994
- Primary biliary cirrhosisJournal of Hepatology, 1993
- A controlled trial of prednisolone treatment in primary biliary cirrhosisJournal of Hepatology, 1992
- Hypercholesterolemia and Atherosclerosis in Primary Biliary Cirrhosis: What Is the Risk?Hepatology, 1992
- Treatment of Postmenopausal Osteoporosis with Calcitriol or CalciumNew England Journal of Medicine, 1992
- Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapyHepatology, 1991
- Efficacy of Liver Transplantation in Patients with Primary Biliary CirrhosisNew England Journal of Medicine, 1989
- D-penicillamine for primary biliary cirrhosis.Gut, 1985